Elevated Serum Sialic Acid Levels Predict Prostate Cancer As Well As Bone Metastases
| Autor: | Zhonghua Xu, Lei Yan, Kui Li, Zeyan Li, Hongkai Song, Liang Fang, Hainan Liu, Feilong Yang, Zheng Ma, Dawei Li, Dongshan Chen, Nengwang Yu, Cong Zhang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Independent predictor Logistic regression urologic and male genital diseases Gastroenterology Elevated serum 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine bone metastases Internal medicine medicine Prognostic biomarker In patient serum sialic acid benign prostatic hyperplasia business.industry Hyperplasia medicine.disease prostate cancer Sialic acid 030104 developmental biology Oncology chemistry 030220 oncology & carcinogenesis business Research Paper |
| Zdroj: | Journal of Cancer |
| ISSN: | 1837-9664 |
| Popis: | Objective: To evaluate the value of serum sialic acid (SA) in diagnosis of benign prostatic hyperplasia (BPH), prostate cancer (PCa), and bone metastases in PCa patients. Materials and Methods: Data from 540 patients who were newly diagnosed with PCa or BPH between November 2014 and March 2018 were retrospectively collected and analyzed. Pretreatment SA levels were compared across various groups, then, associations between SA levels and clinic parameters of patients were analyzed as well. Univariate and multivariate logistic regression analyses were further used to identify independent associations. Results: The mean SA levels in patients with PCa were significantly higher than with BPH (p = 0.013). Furthermore, PCa patients with bone metastases showed elevated SA levels compared with PCa without bone metastases (p < 0.001). A multivariate logistic regression model showed that: SA level > 52.35 mg/dL was identified to be independently associated with the diagnosis of PCa (HR = 1.645, p = 0.036), and SA level > 59 mg/dL was identified to be independent association with the presence of bone metastases in PCa patients (HR = 6.421, p = 0.012). Conclusions: Elevated SA level is an independent predictor of prostate cancer as well as its bone metastases. Therefore, SA level may be a promising diagnostic and prognostic biomarker for prostate cancer and bone metastases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|